Meda License, Development and Supply Agreements (Tables)

9 Months Ended

Sep. 30, 2012

Meda License, Development and Supply Agreements [Abstract]

Summary of contractual rights, obligations and related cash flows

The Company’s rights and obligations under these arrangements and related contractual cash flows from Meda are as follows:

	Cash flows received and revenue deferred
Contractual Rights and Obligations	September 30, 2012			December 31, 2011
North America
License rights to ONSOLIS ® (BEMA® Fentanyl) and milestone payments	$	59,800,000		$	59,800,000
Research and Development Services for:
•       Non-cancer subsequent indication of product and further development of initial product	$	1,541,570		$	1,541,570
Total North America Agreement Milestones	$	61,341,570		$	61,341,570
Europe and Rest of World
License rights to BREAKYL™ (BEMA ® Fentanyl) and milestone payments	$	10,500,000		$	8,000,000
Research and Development Services for:
•       BREAKYL™ product through governmental approval in an E.U. country	$	4,548,720		$	4,548,720
Total Europe and Rest of World Milestones	$	15,048,720		$	12,548,720
Total All Milestones	$	76,390,290		$	73,890,290
Release of Milestones upon and subsequent to first North American sale	$	(59,884,370	)	$	(59,735,570	)
Remaining Deferred Revenue	$	16,505,920		$	14,154,720